New Study Evaluates the Ability of Masimo ORi™ to Help Clinicians Reduce Hyperoxemia in Mechanically Ventilated ICU Patients
1.10.2018 09:00:00 EEST | Business Wire | Press release
Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the 2018 Congress of the French Society of Anesthesia and Resuscitation (SFAR) in Paris in which researchers at CHU Angers in France investigated the ability of Masimo ORi™ (Oxygen Reserve Index) to help clinicians reduce the number of days ICU patients experience hyperoxemia while on mechanical ventilation.1 ORi, available outside the U.S., is a noninvasive and continuous parameter intended as a relative indicator of a patient’s oxygen reserve during moderate hyperoxia (partial pressure of oxygen in arterial blood [PaO2] in the range of 100 to 200 mmHg). ORi can be trended and has optional alarms to notify clinicians of changes in oxygenation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180930005016/en/
Masimo Root® with Radical-7®, ORi™, and RD rainbow SET™ Sensor (Photo: Business Wire)
Noting that hyperoxemia can lead to patient morbidity and mortality in ICU patients, and that oxygen saturation (SpO2) cannot detect hyperoxemia, Dr. Brochant and colleagues sought to evaluate whether ORi might be useful in helping clinicians determine when to reduce the fraction of inspired oxygen (FiO2) during oxygen therapy, so as to avoid hyperoxemia. In this initial analysis, the first 131 patients in the study, whose data were collected between May 2017 and March 2018, were randomly assigned into an ORi and a control group. In the ORi group, FiO2 was reduced if ORi was > 0. In the control group, the FiO2 level was adjusted according to SpO2. Clinicians recorded blood gas results, episodes of atelectasis, and the length of time spent on mechanical ventilation, for up to 28 days. The principal point of comparison was the proportion of ventilated days with hyperoxemia.
The researchers found that the percentage of days with hyperoxemia was significantly lower in the ORi group: median 14% [interquartile range 0-31%], vs. 29% [IQR 11-50%] in the control group, p=0.005. Average daily PaO2 and FiO2 values were not significantly different between the two groups, suggesting that FiO2 was not systematically lowered in the ORi group. The average number of days without ventilation and median time spent in the ICU were also not significantly different.
The researchers concluded that the use of ORi may help clinicians reduce the percentage of days with hyperoxemia, that analysis of the full group of patients may allow assessment of its effect on the occurrence of atelectasis, and that additional studies may be useful in evaluating the impact of this monitoring on the morbidity and mortality of patients.
ORi has not received FDA 510(k) clearance and is not available for sale in the United States.
@MasimoInnovates | #Masimo
Reference
- Brochant A, Dupre P, Gaillard T, Lemarie P, Gergaud S, and Lasocki S. “ORi pour moins d’hyperoxie en reanimation.” Proceedings from SFAR 2018, Paris, France. #R244.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,1 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response activations and costs.3,4,5 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at 9 of the top 10 hospitals listed in the 2018-19 U.S. News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), and more recently, Oxygen Reserve Index (ORi™), in addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect® (MOC-9®) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7® wearable patient monitor, iSpO2 ® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at http://www.masimo.com/evidence/featured-studies/feature/.
ORi has not received FDA 510(k) clearance and is not available for sale in the United States.
The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
References
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
- Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
- Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
- McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
- Estimate: Masimo data on file.
- http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo ORi™. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo ORi, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180930005016/en/
Contact information
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Yonder Announces New Leadership18.11.2026 15:03:00 EET | Press release
Blue Yonder, the AI company for supply chain, today announced that Salil Joshi has been named interim Chief Executive Officer. Joshi has most recently served as Blue Yonder’s Chief Technology Officer, where he led the company’s technology vision and growth strategy across the digital supply chain. Joshi succeeds Duncan Angove, who will transition out of the CEO role after four years leading the company. The Blue Yonder Board appreciates the contributions that Angove has made to the company. “Blue Yonder continues to showcase strong momentum through accelerating Cognitive Solutions adoption in the market. Blue Yonder has reported impressive SaaS ARR growth, adding new customer logos and increasing inclusions in key tech and industry analyst reports,” said Ken Sain, Chairman of the Blue Yonder Board of Directors and CEO of Panasonic Connect Group. “We believe there is a significant additional opportunity to build on that solid foundation to expand the company’s software platform to help
AI Private Markets Platform FinBursa Appoints Angelica Tigan as Chief Revenue Officer to Drive US and Global Growth18.11.2026 15:00:00 EET | Press release
FinBursa, the intelligent front office for private markets, has appointed Angelica Tigan, a former BlackRock and eFront sales leader, as Chief Revenue Officer to lead its global commercial expansion following the launch of FinBursa 360. Based in the US, Tigan will lead sales and partnerships worldwide, with an immediate focus on the US. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118596329/en/ Angelica Tigan, based in New York City, joins FinBursa as Chief Revenue Officer Tigan brings close to two decades in private markets technology, having built, led and scaled sales teams at BlackRock (Aladdin) and eFront, with previous experience at Intralinks and Gen II Fund Services. FinBursa 360 is an all-in-one platform for private equity, private credit, real estate, venture capital and M&A advisory firms, family offices, wealth managers, placement agents and fund administrators. It brings investment CRM, deal flow and deal m
Scientist.com Launches Pharma Observatory, an Agent-First Market Intelligence Platform for Biopharma R&D18.11.2026 14:55:00 EET | Press release
Scientist.com, the leading AI-enabled R&D orchestration platform and marketplace for the life science industry, today announced the launch of Pharma Observatory, a market intelligence platform that shows biopharma teams where their programs sit in the wider market. Scientist.com helps research teams drive a project forward. Pharma Observatory places that project in context: who else is working on the same target or indication, who the likely partners and acquirers are, and what the eventual clinical trials are likely to look like. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118907460/en/ Scientist.com's Pharma Observatory brings nearly 1 billion records from ~100 public sources (ClinicalTrials.gov, FDA, USPTO, NIH, SEC) into one cross-referenced model. The public record on biopharma is huge but scattered. ClinicalTrials.gov, the FDA, SEC filings, PubMed, NIH, the USPTO and dozens of other sources each publish part of t
Helical Fusion Awarded Up to JPY 19.2 Billion in Japanese Government Funding to Accelerate Commercial Fusion Power18.11.2026 14:36:00 EET | Press release
Helical Fusion Co., Ltd., a fusion energy company developing commercially viable power plants based on Helical Stellarator technology, has been formally selected for a major Japanese government grant program administered by the Ministry of Economy, Trade and Industry (METI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118128278/en/ The maximum government subsidy is approximately JPY 19.2 billion (USD 126 million). The grant-supported project is scheduled to run through February 2029. Through the Helix Program, Helical Fusion leads overall plant design and systems integration, drawing on research from Japan’s national research institutions and the engineering and manufacturing expertise of approximately 40 companies in Japan. The program aims to turn Japan’s scientific and industrial strengths into practical fusion power. The funding will accelerate three areas of development: Helix HARUKA: Manufacturing and assembly of
New TOURISE Report Reveals How Traveler Expectations Are Changing the Rules for Global Tourism18.11.2026 14:00:00 EET | Press release
Changing traveler priorities are reshaping global tourism, influencing where people go, how they spend and what they value most from their journeys. A new report released by TOURISE, The Future Traveller, explores these shifts and what they mean for the industry through 2030. Developed in collaboration with Euromonitor International, the report draws on consumer surveys and perspectives from industry leaders. The report finds that travel decisions are increasingly shaped by the priorities and circumstances of each trip, rather than demographics alone. It calls on destinations and businesses to rethink how they attract visitors and measure success, shifting the focus from high-spending travelers to high-value trips that deliver meaningful experiences, support local economies and create lasting benefits for communities. “Travelers are not making decisions as fixed demographic segments. They are responding to purpose, pressures and possibilities of each trip,” said His Excellency Ahmed Al
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
